Status:
COMPLETED
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
Lead Sponsor:
Yale University
Collaborating Sponsors:
Forest Laboratories
Conditions:
Alcohol Dependence
Schizophrenia
Eligibility:
All Genders
21-65 years
Phase:
PHASE3
Brief Summary
The aim of this study is to evaluate the safety and efficacy of acamprosate for patients with alcohol dependence and comorbid schizophrenia spectrum disorders. * 1: Relative to placebo, acamprosate w...
Detailed Description
Alcohol use disorders (AUD) are common comorbid conditions in patients with schizophrenia, and they cause a negative impact on the expression and course of schizophrenia. Improvements have been report...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Men and women between 21 and 65 years of age.
- Patients with a diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder NOS as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) \[22\].
- Patients who are on stable treatment with psychotropic medication \> 2 weeks prior to randomization.
- Patients with current alcohol dependence, with at least one recent episode of heavy drinking (defined as 5 or more drinks per drinking episode) over the past 21 days, and willing to undergo detoxification or self discontinuation (for at least 5 days).
- Patients, who are able to comprehend and satisfactorily comply with protocol requirements.
- Patients who have capacity to provide informed consent prior to entering any study procedure.
- Exclusion Criteria
- Patients with dementia, amnestic and other cognitive disorders.
- Patients who have unstable medical disease or a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial
- Patients with a history of opioid dependence within the past month.
- Patients with a history of intolerance or hypersensitivity to acamprosate.
- Patients who are currently taking disulfiram or naltrexone.
- Patients who based on history or mental status examination are at a significant risk for suicide.
- Patients who are homicidal or violent and who are in the Investigator's opinion in significant imminent risk of hurting others.
- Women who are pregnant or nursing, or women of childbearing potential who are sexually active and who do not use adequate contraception, or who are judged to be unreliable in their use of contraception.
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00463346
Start Date
September 1 2006
End Date
July 1 2015
Last Update
March 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516